Key result
Cardiac magnetic resonance imaging provides reliable parameters, such as infarct size and myocardial salvage, that are potentially suitable as surrogate endpoints in clinical trials of acute myocardial infarction.
CMR provides valuable surrogate endpoints for STEMI clinical trials, offering mechanistic insights and methodological advantages over traditional imaging modalities like SPECT.
May support CMR surrogates for efficient AMI trials; leaves open outcome validation before routine adoption.
Cardiac magnetic resonance (CMR) offers a variety of parameters potentially suited as surrogate endpoints in clinical trials of acute myocardial infarction such as infarct size, myocardial salvage, microvascular obstruction or left ventricular volumes and ejection fraction. The present article reviews each of these parameters with regard to the pathophysiological basis, practical aspects, validity, reliability and its relative value (strengths and limitations) as compared to competitive modalities. Randomized controlled trials of acute myocardial infarction which have used CMR parameters as a primary endpoint are presented.
No takes yet. Share an insight, caveat, or question.
Desch et al. (2011) conducted a review in Acute myocardial infarction. Cardiac magnetic resonance imaging (CMR) parameters was evaluated. Cardiac magnetic resonance imaging provides reliable parameters, such as infarct size and myocardial salvage, that are potentially suitable as surrogate endpoints in clinical trials of acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: